tiprankstipranks
Trending News
More News >
ImmuPharma PLC (GB:IMM)
LSE:IMM

ImmuPharma (IMM) Stock Statistics & Valuation Metrics

Compare
20 Followers

Total Valuation

ImmuPharma has a market cap or net worth of £12.29M. The enterprise value is 23.21M.
Market Cap£12.29M
Enterprise Value23.21M

Share Statistics

ImmuPharma has 499,723,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding499,723,940
Owned by Insiders
Owned by Institutions

Financial Efficiency

ImmuPharma’s return on equity (ROE) is -2.77 and return on invested capital (ROIC) is -247.82%.
Return on Equity (ROE)-2.77
Return on Assets (ROA)-1.07
Return on Invested Capital (ROIC)-247.82%
Return on Capital Employed (ROCE)-2.90
Revenue Per Employee0.00
Profits Per Employee-584.36K
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of ImmuPharma is -2.06. ImmuPharma’s PEG ratio is 0.17.
PE Ratio-2.06
PS Ratio0.00
PB Ratio4.66
Price to Fair Value5.70
Price to FCF-5.67
Price to Operating Cash Flow-5.82
PEG Ratio0.17

Income Statement

In the last 12 months, ImmuPharma had revenue of 0.00 and earned -2.92M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-37.61K
Operating Income-3.06M
Pretax Income-3.42M
Net Income-2.92M
EBITDA-3.02M
Earnings Per Share (EPS)-0.01

Cash Flow

In the last 12 months, operating cash flow was -1.59M and capital expenditures 2.00, giving a free cash flow of -1.59M billion.
Operating Cash Flow-1.59M
Free Cash Flow-1.59M
Free Cash Flow per Share>-0.01

Dividends & Yields

ImmuPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.80
52-Week Price Change17.94%
50-Day Moving Average2.80
200-Day Moving Average2.51
Relative Strength Index (RSI)44.45
Average Volume (3m)2.69M

Important Dates

ImmuPharma upcoming earnings date is Sep 25, 2025, TBA Not Confirmed.
Last Earnings DateMay 19, 2025
Next Earnings DateSep 25, 2025
Ex-Dividend Date

Financial Position

ImmuPharma as a current ratio of 0.81, with Debt / Equity ratio of 0.51%
Current Ratio0.81
Quick Ratio0.81
Debt to Market Cap0.00
Net Debt to EBITDA0.07
Interest Coverage Ratio-1.54K

Taxes

In the past 12 months, ImmuPharma has paid -497.00K in taxes.
Income Tax-497.00K
Effective Tax Rate0.15

Enterprise Valuation

ImmuPharma EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -4.26.
EV to Sales0.00
EV to EBITDA-1.92
EV to Free Cash Flow-4.26
EV to Operating Cash Flow-4.26

Balance Sheet

ImmuPharma has £1.08M in cash and marketable securities with £0.00 in debt, giving a net cash position of -£1.08M billion.
Cash & Marketable Securities£1.08M
Total Debt£0.00
Net Cash-£1.08M
Net Cash Per Share>-£0.01
Tangible Book Value Per Share<£0.01

Margins

Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for ImmuPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis